Achillion Pharmaceuticals Inc., of New Haven, Conn., promoted Milind Deshpande to chief scientific officer and senior vice president of research, and Kevin Eastwood to senior vice president of business development.

Affimed AG, of Heidelberg, Germany, appointed Gavin Clark executive vice president business development, and Florian Fischer chief financial officer.

AGY Therapeutics Inc., of South San Francisco, appointed Larry Powe vice president of clinical development.

airPharma, of Overland Park, Kan., appointed Nita Cogburn to oversee Zofac, and Susan Prather to manage development of Axifa.

Alda Pharmaceuticals Corp., of Vancouver, British Columbia, appointed William McCoy to its board.

Alexion Pharmaceuticals Inc., of Cheshire, Conn., appointed David Keiser as interim chief financial officer.

American Esoteric Laboratory Services, of Nashville, Tenn., appointed Chuck Locke vice president of development and administration.

Archemix Corp., of Cambridge, Mass., appointed Frank Douglas to its board.

Avant Immunotherapeutics Inc., of Needham, Mass., appointed Timothy Cooke chief operating officer.

Banc of America Securities LLC in New York hired David Witzke as a principal and equity research analyst covering biotechnology.

Baxter International Inc., of Deerfield, Ill., named Susan Lichtenstein corporate vice president, general counsel and corporate secretary, and Peter Arduini corporate vice president and president of its medication delivery business. It also appointed Blake Devitt to its board.

Benitec Ltd., of St. Lucia, Australia, appointed Katherine High to its scientific advisory board.

Biocom, of San Diego, appointed Jack Lief chairman and added new board members Dana Di Ferdinando, Larry Fitch, Mary Lyons, Randall Woods and Kleanthis Xanthopoulos.

Biomarker Technologies LLC, of Phoenix, appointed Amy Armstrong director of communications.

BrainStorm Cell Therapeutics, of Tel Aviv, Israel, appointed Ole Isacson to its scientific advisory board.

CepTor Corp., of Hunt Valley, Md., appointed Jerry Mendell to its scientific advisory board.

Ciphergen Biosystems Inc., of Fremont, Calif., appointed James Merryweather executive vice president, pharmaceutical corporate development.

DOR BioPharma Inc., of Miami, appointed George Robertson vice president of research.

Emergent BioSolutions Inc., of Gaithersburg, Md., appointed Jonathan Pockson senior vice president and chief financial officer.

Encysive Pharmaceuticals Inc., of Houston, appointed Toby Juvenal vice president of sales, and Morris Cheeks senior director of medical affairs.

Exagen Diagnostics Inc., of Albuquerque, N.M., appointed Thomas Williams special adviser for molecular pathology.

Fujirebio Diagnostics Inc., of Malvern, Pa., promoted Peter Minetti vice president of quality and regulatory compliance.

Theratechnologies Inc., of Montreal, appointed James Sutton vice president, clinical development and regulatory affairs, and Robert Goyer to its board.

Voyager Pharmaceutical Corp., of Raleigh, N.C., appointed Sheldon Goldberg senior vice president of corporate development.

XOMA Ltd., of Berkeley, Calif., nominated Peter Barton Hutt to its board.